The Imperial College London Diabetes Centre (ICLDC), part of the M42 group, has signed two significant agreements at Arab Health in Dubai, underscoring its commitment to advancing diabetes care through patient empowerment and precision medicine.
ICLDC's first agreement, in collaboration with Medtronic, aims to enhance its diabetes care services for over 1,000 patients in Abu Dhabi. The centre, which currently utilizes Medtronic's CareLink™ platform, will transition to Medtronic’s advanced CareConnect and GALAXY platforms. CareConnect, designed to be more patient-centric, offers a streamlined interface and customizable notifications for critical events, enabling caregivers to monitor patients remotely. The platform integrates remote patient monitoring, ensuring timely interventions and reducing in-person visits.
In addition, the GALAXY platform will provide tailored reporting, offering clinicians and researchers comprehensive patient insights, improving both individual care and operational strategies.
ICLDC is also collaborating with Karaz, an innovative healthcare platform, to simplify data integration. The Karaz platform will consolidate patient information from various devices into a single, user-friendly dashboard, enhancing efficiency for caregivers.
Dr. Mai Al Jaber, CEO of Outpatient Care at M42, remarked,
"This partnership marks a transformative step in diabetes care, enabling us to offer proactive, personalized treatments and better outcomes. Through CareConnect, GALAXY, and Karaz, we are leading the integration of advanced technologies to revolutionize diabetes management locally and globally."
These agreements represent ICLDC’s ongoing efforts to reshape diabetes care, making it more accessible, efficient, and focused on individual patient needs.
News Source: Emirates News Agency
